Adrenal incidentalomas are incidentally discovered adrenal masses greater than 1 cm in diameter that appear to be clinically nonfunctioning. They are detected during imaging procedures of the abdomen and chest (CT, MRI, and ultrasonography) for an unrelated condition or symptom complex. With the widespread escalation in the use of these imaging modalities and marked improvements in image resolution, the probability of finding an incidentaloma on cross-section imaging is rapidly approaching the 6% prevalence of previously reported autopsy studies. All incidentalomas greater than 1 cm should be evaluated for hormonal activity, including a 1-mg overnight dexamethasone suppression test, total 24-hour urinary metanephrines and fractionated catecholamines, and, in the hypertensive patient, a serum potassium level and plasma aldosterone concentration to plasma renin activity ratio. All hormonally active tumors should be removed. Hormonally inactive tumors are resected based on size, imaging phenotype, and interval growth. Percutaneous biopsies are generally unwarranted and are potentially dangerous. Laparoscopic adrenalectomy has become the surgical procedure of choice for most benign functioning and nonfunctioning tumors of the adrenal gland. Subclinical metabolic abnormalities associated with adrenal incidentalomas remain an area of intense clinical research. Curr Oncol 2003, 15:84-90 
Prevalence
Seemingly common and unimportant adrenal nodules have been recognized for decades [1] . The overall frequency of adrenal adenomas in more than 85,000 autopsies from 25 reported studies was 5.9% (range, 1-32%) [2, 3] . With the widespread escalation in the application of CT, MRI, ultrasonography, isotopic scanning, and positron emission tomography, and improved image resolution, the probability of finding an adrenal incidentaloma on cross-sectional imaging of the abdomen or chest is increasing. Previous estimates of 1% likely reflect early technology with limited image resolution. Several studies have correlated the presence of adrenal nodules with age (younger than 30 years, 0.2%; older than 70 years, 6.9%) [4] [5] [6] . It is likely that with improved technology, frequencies comparable with autopsy studies will be seen.
Differential diagnosis
The overwhelming majority of adrenal incidentalomas are nonfunctioning cortical adenomas. Nearly 40 different diagnoses have been associated with adrenal incidentaloma (Tables 1 and 2) [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] . In a literature review of more than 2000 incidentalomas [7], 82% were nonfunctioning adenomas, 5.3% were subclinical Cushing syndrome (SCS), 5.1% were pheochromocytomas, 1.0% were aldosterone-producing adenomas, 4.7% were adrenocortical carcinomas, and 2.5% were metastatic disease. The incidence of metastatic disease increases dramatically in patients with a known previous malignancy.
Basic science
The molecular mechanisms that result in the formation of adrenocortical tumors are being actively investigated and were recently reviewed by Bertherat et al. [21] . Activating mutations of the GNAS-1 gene can be found in the form of bilateral macronodular adrenal hyperplasia seen in McCune-Albright syndrome [22] .
Gastrointestinal polypeptide (GIP, an insulinotropic peptide secreted from the duodenum after food ingestion) has been shown in vitro to be as potent as adrenocorticotropic hormone (ACTH) in stimulating cortisol se-cretion from fragments of tumorous or hyperplastic adrenal tissue with food-dependent hypercortisolism. Reverse-transcription polymerase chain reaction studies have shown the abnormal expression of the GIP receptor in the tumorous adrenal glands of patients with this disorder, but very low expression in the adjacent nontumorous cortex [21] .
The role of insulin-like growth factors and the consequences of 11p15 region abnormalities are being studied in adrenocortical carcinomas [23] .
Loss of heterozygosity at 17p13 is high in adrenocortical tumors. Only 20% of adrenocortical cancers have p53 mutations (which are included in the 17p13 region), suggesting that other tumor suppressor genes as yet unidentified are required for adrenal tumorigenesis [24] . Serum metalloprotease MMP-3 (stromyelisine) and vascular endothelial growth factor were found to be signifi-cantly higher in patients with malignant adrenal incidentalomas than in those with benign tumors. Levels decreased after tumor resection and increased significantly in patients with recurrence. Their roles as clinical tumor markers are being explored [25••,26] .
Diagnostic evaluation
In approaching the patient with an adrenal incidentaloma, two questions must be answered before any therapeutic decision: (1) is the mass hormonally active, and (2) could the mass be a potentially curable malignancy, either primary or metastatic? History and physical examination should precede all other studies.
Hormonal evaluation
Subclinical Cushing syndrome was first described in 1981. Patients with SCS have autonomous cortisolsecreting adenomas, yet lack the typical signs and symptoms of overt Cushing syndrome [27] . SCS is the most frequent hormonal abnormality detected in patients with adrenal incidentaloma (5.4%) [7] . Although these patients lack the typical stigmata of Cushing syndrome, they may exhibit more subtle sequelae of continuous endogenous cortisol hypersecretion. These findings may include insulin resistance, hypertension, osteoporosis, and obesity, all common problems in our aging Western culture. This has been an area of intense clinical research . Preoperative recognition of this entity is important not only to take advantage of the potential healthcare benefit but also to avoid acute adrenal insufficiency in the perioperative period after the removal of a seemingly nonfunctioning adenoma.
Because ACTH assays are not very sensitive at the lower range of normal, suppression testing is mandatory [7] . Most centers rely on the 1-mg overnight dexamethasone suppression test. If the 8 a.m. plasma cortisol level is greater than 5 µg/dL, a formal 2-day low-dose or highdose dexamethasone suppression test is indicated to confirm autonomy [7] . Twenty-four-hour urinary-free cortisol greater than 20 µg when measured by radioimmunoassay (RIA) or greater than 5 µg when measured by high-pressure liquid chromatography (HPLC) after these studies warrants adrenalectomy for a solitary adrenal incidentaloma [7] . Weight loss, improvement in hypertension and glycemic control, and normalization of markers of bone turnover are found after unilateral adrenalectomy in patients with SCS [36]. Perioperative glucocorticoid coverage is mandatory.
Pheochromocytoma
At Mayo Clinic, 10% of adrenal incidentalomas have proven to be pheochromocytomas [37] . The authors have found that 7% of pheochromocytoma patients have nor- 
Sex hormone-secreting tumors and 21-hydroxylase deficiency
Sex hormone-secreting tumors are very rare and are usually symptomatic, except for testosterone-secreting tumors in men. Routine screening of adrenal incidentalomas for estradiol, testosterone, their precursors, or metabolites is not practical.
Rare cases of nonclassical congenital adrenal hyperplasia have presented with an unilateral adrenal mass. Unless suspected on clinical grounds, routine measurements of 17␣-OH progesterone, cosyntropin testing, and genetic screening are unwarranted [7].
Adrenocortical carcinoma
The 5-year survival rate for all patients with adrenocortical carcinoma is approximately 16%, whereas survival is improved for smaller tumors confined to the adrenal gland (42% 5-year survival) [42] . Only one third of patients with adrenocortical carcinoma present with stage I or II disease [43] . One half are hormonally functioning. Polyhormonal production is common, and elevated precursors (eg, dehydroepiandrostenedione-sulfate) may also be present. Early recognition and surgical intervention are the mainstay of therapy and provide the only chance for long-term survival.
Despite the lethal nature of these tumors, they are fortunately rare. The risk of primary malignancy in unselected incidentaloma cases is 0.1%. In surgical series, the frequency rises to 4 to 5% [7]. The challenge is to avoid missing a small, nonfunctioning adrenocortical carcinoma without performing too many adrenalectomies for benign, inactive tumors. Size, imaging phenotype, and in- terval growth are the best criteria available today for differentiating benign from malignant tumors.
Size and interval growth
Small adrenocortical carcinomas (<4 cm) have been reported [8, 13, 14, [44] [45] [46] [47] [48] but are exceedingly rare. Most adrenocortical carcinomas measure, on average, more than 10 cm when discovered. Recommendations for removing all tumors greater than 3, 4, 5, and 6 cm have been reported [7] . The authors have never encountered an adrenocortical carcinoma less than 5 cm in an adult at Mayo Clinic and have therefore found 4 cm to be an appropriate cutoff above which all indeterminate tumors should be removed. This criterion minimizes the number of unnecessary operations and avoids missing virtually all adrenocortical carcinomas. In one study, a 4-cm cutoff had a 90% sensitivity for detecting adrenocortical carcinoma, even though 76% of lesions greater than 4 cm were benign [49] .
Interval growth is also used as a criterion for surgical intervention. Despite the fact that as many as 25% of adrenal incidentalomas increase in size by at least 1 cm over time, the overwhelming majority of these turn out to be benign. Rapid growth, on the other hand, is very worrisome for malignancy.
Imaging phenotype
Perhaps as important if not more important than size in determining malignant potential are the imaging characteristics as seen on CT and MRI.
Adrenocortical adenomas tend to be small, smooth, homogeneous, and round to oval in shape. They display limited contrast enhancement and appear isodense to liver on T2-weighted images. Necrosis, hemorrhage, and calcifications are rare. Radiograph attenuation on noncontrast CT is usually less than 10 Hounsfield units.
Adrenocortical carcinomas are typically large, with irregular borders and unclear margins. They tend to be inhomogeneous with areas of necrosis, hemorrhage, and calcification. They are quite vascular with strong contrast enhancement. Radiograph attenuation on noncontrast CT is greater than 10 Hounsfield units, and these tumors tend to light up on T2-weighted magnetic resonance images. Metastases (lung, breast, kidney, gastrointestinal tract) display similar characteristics but are more often small and bilateral.
Pheochromocytomas tend to be round to oval with smooth margins. They can be inhomogeneous with cystic areas. Necrosis, hemorrhage, and calcification are common in both benign and malignant lesions. Pheochromocytomas are usually vascular with marked contrast enhancement and tend to be extremely bright (hyperintense) on T2-weighted magnetic resonance images. Bilaterality is common in familial settings (multiple endocrine neoplasia IIa, multiple endocrine neoplasia IIb, and von Hippel-Lindau disease). Isotopic scanning with metaiodobenzylguanidine can be helpful primarily when looking for bilateral, recurrent, or metastatic disease.
NP-59 iodocholesterol scintigraphy has been advocated by some to aid in differentiating benign from malignant cortical lesions and to document aldosterone-producing adenomas. Its utility is limited because of isotope availability, lengthy preparation and test time, and cost. An investigational new drug approval is required [50].
The role of positron emission tomography scanning remains to be determined. 
Biopsy of adrenal incidentalomas
Biopsy is rarely indicated and is fraught with diagnostic and clinical hazards. Biopsies can rarely differentiate benign from malignant adrenocortical tumors. Biopsy of adrenomedullary tumors can precipitate life-threatening hemorrhage and hypertension. Local recurrence from needle-tract seeding or capsular disruption presents a formidable management problem that may not become apparent for years to come. Surrounding tissue reaction may make an otherwise easy laparoscopic resection impossible and dangerous. Adrenal incidentalomas should never be biopsied until a pheochromocytoma is ruled out biochemically.
In patients with a known extraadrenal primary malignancy and a new adrenal mass, biopsy is appropriate to rule out metastatic disease. Unilateral adrenalectomy for isolated solitary metastases may be appropriate therapy in highly selected cases, especially if pain is an issue. Biopsy may also be indicated when adrenal insufficiency is present and systemic infectious or infiltrative processes are suspected. In these cases, the process is virtually always bilateral.
Miscellaneous adrenal incidentalomas
Nonfunctioning cysts, myelolipomas, and adrenal hemorrhage can be observed. Cystic pheochromocytomas must be ruled out, and patients with spontaneous adrenal hemorrhage should be followed to resolution to rule out an underlying neoplasm.
Follow-up
Tumors that are nonfunctioning and less than 4 cm in size with benign radiographic phenotypes and no interval growth can be safely observed. The authors generally recommend repeat imaging at 3 and 12 months, with a repeat functional assessment at 12 and 24 months. If there is no change over the 24-month period in size, phenotype, and function, no further evaluation is required. For all other scenarios, adrenalectomy is recommended for all but the most infirm patients [7] (Fig. 1) . A recent report of robotic-assisted adrenalectomy has been described. The ultimate value of this expensive technology in simplifying minimal access adrenalectomy remains to be seen [57••] .
Conclusions
The decision to resect adrenal incidentalomas should be based on hormonal function, size, interval growth, and radiographic phenotypes. Laparoscopic adrenalectomy is the procedure of choice for most functioning and nonfunctioning benign tumors less than 8 cm in diameter.
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